Compare Ford Motor Company (F) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Novo Nordisk A/S — how do they compare? Ford Motor Company trades at $12.18 (market cap $48.85B), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3.4× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Novo Nordisk A/S for 116 Days on average.
| F | NVO | |
|---|---|---|
Market Cap | $48.85B | $165.31B |
Volume | 57,748,965 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $63.98 |
52-Week Low | $11.21 | $35.29 |
Typical Hold Time | 104 Days | 116 Days |
Enterprise Value | $180.81B | $179.56B |
Dividend Yield | 4.9% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.125, down 1.22% on the day, amid a challenging quarter with a 6.6% sales decline reported for Q3 2026 (Reuters, 2026-10-02). The stock shows a bearish technical signal, with moving averages indicating a downtrend. Fundamentally, the company reported a net loss of $8.18 billion for 2025, with negative profit margins and ROE, though operating cash flow remains strong at $21.28 billion. Recent news highlights supplier disruptions affecting F-150 production and a strategic shift toward hybrids.
The outlook for Ford is mixed, with analyst consensus leaning toward a 'Hold' (48.93% of ratings) and a price target of $15.90 suggesting potential upside. Key opportunities include the growing hybrid segment and strong commercial division, while risks involve ongoing sales volatility, high debt levels, and competitive pressures from Asian automakers. Investors should weigh the company's cash flow strength against profitability challenges and market share losses.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
